Bestrophin-4 inhibitors are a class of chemical compounds that specifically target and inhibit the function of **Bestrophin-4**, a member of the bestrophin family of proteins known for their roles as calcium-activated chloride channels. Bestrophin-4 is primarily expressed in various tissues, including the retina, where it plays a significant role in regulating ion transport and maintaining the resting membrane potential of cells. By inhibiting Bestrophin-4, these compounds disrupt chloride ion flux across the cell membrane, leading to alterations in cellular excitability, signaling, and homeostasis. The inhibition of Bestrophin-4 can provide researchers with essential tools to investigate the physiological roles of chloride channels in different cellular contexts.
The study of Bestrophin-4 inhibitors allows scientists to delve into the functional implications of altered chloride channel activity on cellular processes such as fluid transport, electrical signaling, and the regulation of intracellular calcium levels. By manipulating Bestrophin-4 function, researchers can assess how changes in ion transport impact cellular behavior, including processes such as migration, differentiation, and communication with neighboring cells. Furthermore, these inhibitors facilitate the exploration of the molecular mechanisms governing ion channel regulation and the potential interactions with other ion transporters. Through these investigations, Bestrophin-4 inhibitors contribute to a broader understanding of ion channel physiology, enhancing knowledge of how chloride channels influence various biological functions and the intricate balance of ion homeostasis in different tissues.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This agent could induce DNA demethylation, leading to the repression of Bestrophin-4 gene transcription through changes in chromatin structure. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic Acid may initiate a signaling cascade that results in the downregulation of Bestrophin-4 through altered transcription factor binding. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate could deplete nucleotide pools, leading to a decrease in Bestrophin-4 mRNA synthesis by hindering nucleotide availability. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea may reduce the pool of deoxyribonucleotides, causing a decrease in DNA replication and a subsequent reduction in Bestrophin-4 mRNA. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium Butyrate could inhibit histone deacetylases, causing hyperacetylation of histones and downregulation of Bestrophin-4 gene expression. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein, through its tyrosine kinase inhibition, could disrupt cellular signaling pathways, leading to the decreased expression of Bestrophin-4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 might inhibit PI3K, leading to a cascade of events that culminate in the decreased transcription of the Bestrophin-4 gene. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
By inhibiting the MEK pathway, PD 98059 could decrease phosphorylation of transcription factors, resulting in reduced expression of Bestrophin-4. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 could inhibit JNK activity, leading to downregulation of transcription factors and a subsequent decrease in Bestrophin-4 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 may inhibit p38 MAPK, altering the activity of transcription factors and leading to the reduced expression of the Bestrophin-4 gene. |